Nivolumab Immunotherapy-Related Skin Reactions Detected on 18F-FDG PET/CT in Renal Cell Cancer.
Where this comes from
- Record sourced from PubMed, PMID 35439194.
- Also identified by DOI 10.1097/RLU.0000000000004224.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Nivolumab, a fully human immunoglobulin G4 anti-programmed cell death 1 antibody, provides a novel therapy option for patients with metastatic cancers. Immunotherapy agents have been associated with immune-related adverse events (irAEs), which may be detected on 18F-FDG PET/CT. Cutaneous toxicities are one of the most common irAEs in the form of maculopapular rash (eczema-like spongiotic dermatitis) and pruritus. These irAEs may lead to false-positive findings on PET/CT done during the treatment. One should be aware of the potential irAEs while interpreting PET/CT to avoid misinterpretation.
Medical subject headings
- Antineoplastic Agents, Immunological
- Carcinoma, Renal Cell
- Kidney Neoplasms